Loading
Latest filing published 01 Oct 2025 for SAB Biotherapeutics, Inc., €2.6M.
No signal scores available.
This profile gathers the share dealings of Andrew Moin in SAB Biotherapeutics, Inc. Over a trading history stretching from 24 November 2023 to 29 September 2025, the count stands at 2 filings.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
On 1 October 2025 came the latest disclosure, an option exercise for €2.6M in SAB Biotherapeutics, Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 of 2 declarations